Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for treating chronic cardiac failure and application thereof

A technology for chronic heart failure and a composition is applied in the field of medicine to achieve the effects of reducing left ventricular end-diastolic pressure, improving quality of life, and reducing drug side effects

Inactive Publication Date: 2014-08-27
纪村传
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, in the treatment of heart failure, there are no reports in the literature that use N-methyltyramide or N-methyltyramine in combination with an angiotensin-converting enzyme inhibitor as the main active ingredient.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating chronic cardiac failure and application thereof
  • Pharmaceutical composition for treating chronic cardiac failure and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Example 1 Effect of captopril combined with N-methyltyramine on animal model of abdominal aortic coarctation

[0022] There were 75 male SD rats, weighing 200-220 g, randomly selected 15 rats as the sham operation group (the surgical silk thread was passed through the abdominal aorta after laparotomy in the sham operation group, but the abdominal aorta was not ligated), and the remaining 80 rats were large Rats were prepared as animal models of abdominal aortic coarctation as follows: after skin preparation, the rats were anesthetized with 10% chloral hydrate 3 mL / kg intraperitoneally, a median incision was made in the lower abdomen under the xiphoid process, the abdominal cavity was opened in layers, and blunt injection was performed above the renal artery branch. Free the abdominal aorta, place the No. 7 syringe needle parallel to the abdominal aorta, ligate the abdominal aorta and the needle with No. 4 surgical silk thread, and then withdraw the needle slowly, resulti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition for treating chronic cardiac failure and application thereof. The pharmaceutical composition contains the following two active ingredients: (1), N-methyltyramine or a medicinal salt thereof; (2), any one angiotensin converting enzyme inhibitor. The pharmaceutical composition disclosed by the invention can be used for cooperatively increasing left ventricular systolic pressure, lowering left ventricular end diastolic pressure and improving the sexual function of a rat with chronic cardiac failure, so that the cardiac hypertrophy symptom of a heart failure patient can be reversed, and the effect for treating chronic cardiac failure can be brought into play.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a pharmaceutical composition for treating chronic heart failure and its application. Background technique [0002] Chronic heart failure (CHF) is a complex clinical symptom group, which is the terminal stage of various heart diseases, and its morbidity and mortality are high. According to statistics, the prevalence rate of the general population is about 1.0% to 2.0%, and it can reach 6% to 10% over the age of 65. According to the results of a random sampling survey of 15,518 urban and rural residents aged 35 to 74 in my country, the prevalence of heart failure is 0.9%, and there are about 4 million heart failure patients according to calculations, of which 0.7% are males and 1.0% are females. male. As the population ages, its prevalence is on the rise. In patients over 65 years of age, CHF was the leading cause of hospitalization. For this reason, the treatment o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/137A61P9/04A61K31/401
Inventor 纪村传周娜赵翠徐光红
Owner 纪村传
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com